Vahdat Mansureh, Kashanian Maryam, Ghaziani Negar, Sheikhansari Narges
Iran University of Medical Sciences, Department of Obstetrics & Gynecology, Akbarabadi Teaching Hospital, Tehran, Iran.
Iran University of Medical Sciences, Department of Obstetrics & Gynecology, Akbarabadi Teaching Hospital, Tehran, Iran.
Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:74-78. doi: 10.1016/j.ejogrb.2016.08.013. Epub 2016 Aug 9.
Myoma is one of the most common benign tumors of uterus and one of the most common causes of vaginal bleeding in women. The purpose of the present study is to evaluate the effect of dopamine receptor agonist cabergoline on the size of myoma and the amount of bleeding in the women with myoma of the uterus.
The study was performed as a single blind randomized clinical trial on the women with symptomatic myoma. The women were randomly assigned in 2 groups. In the case group, 0.5mg cabergoline was prescribed weekly for three months, and in the control group, nothing was prescribed and the women only had close observation for symptoms. The reduction in symptoms including pelvic pain and duration and amount of uterine bleeding, and the size of myoma, were compared between the 2 groups.
51 women finished the study (26 women in the case group and 25 women in the control group). There was no significant difference between the 2 groups according to age, gravidity, parity, history of abortion, having living children, pretreatment hemoglobin, pain and amount of uterine bleeding, uterine size, and the size of myoma. After treatment, hemoglobin levels had dropped in the control group but not in the case group (p=0.004). On the other hand, pain had also decreased significantly in the case group in comparison with the control group (p=0.001). Also, the amount of menstrual bleeding (p=0.004), uterine size (p=0.001) and the size of the largest myoma (p=0.013) showed significant reduction in the case group.
Cabergoline can decrease the amount of bleeding and pain in the cases of myomatous uterus and can be used for the symptomatic women who want to preserve uterus for a certain period of time.
子宫肌瘤是女性子宫最常见的良性肿瘤之一，也是女性阴道出血的最常见原因之一。本研究的目的是评估多巴胺受体激动剂卡麦角林对子宫肌瘤大小及子宫肌瘤女性出血量的影响。
本研究作为一项单盲随机临床试验，针对有症状的子宫肌瘤女性进行。这些女性被随机分为两组。病例组每周服用0.5毫克卡麦角林，持续三个月，而对照组未给予任何药物治疗，仅密切观察症状。比较两组之间包括盆腔疼痛、子宫出血的持续时间和出血量以及肌瘤大小等症状的减轻情况。
51名女性完成了研究（病例组26名女性，对照组25名女性）。两组在年龄、妊娠次数、产次、流产史、存活子女数、治疗前血红蛋白、疼痛和子宫出血量、子宫大小以及肌瘤大小方面无显著差异。治疗后，对照组血红蛋白水平下降，而病例组未下降（p = 0.004）。另一方面，与对照组相比，病例组疼痛也显著减轻（p = 0.001）。此外，病例组月经出血量（p = 0.004）、子宫大小（p = 0.001）和最大肌瘤大小（p = 0.013）均显著减小。
卡麦角林可减少子宫肌瘤患者的出血量和疼痛，可用于希望在一定时期内保留子宫的有症状女性。
